Ruiz P, Rodríguez-Cano F, Zerolo F J, Casal M
Centro de Referencia de Micobacterias, Facultad de Medicina, Universidad de Cordoba, Cordoba, Spain.
Rev Esp Quimioter. 2003 Jun;16(2):188-94.
Streptomycin was the first antibiotic to be used against Mycobacterium tuberculosis. It was used for years in monotherapy regimens, thereby resulting in the appearance of resistance and the relegation of its use. The resistance detected against drugs currently employed has led to a renewed interest in streptomycin. Its mechanism of action is centered on the ribosome, inhibiting the protein synthesis of the microbacteria. Resistance appears when mutations in the genes codifying for rRNA 16S and for protein S12 are produced. We studied the use of streptomycin against 899 M. tuberculosis strains, 713 of which were from pulmonary and 186 from extrapulmonary isolates. The BACTEC 460 TB system was initially employed as was the ESP II system. As controls, the ATCC27294 pattern strains (susceptible to streptomycin, rifampicin, ethambutol and isoniazid) were used. The results showed 2.1% secondary resistance in all the cases. Multiresistance was observed in 12 strains.
链霉素是第一种用于对抗结核分枝杆菌的抗生素。它多年来一直用于单一疗法，从而导致耐药性的出现并减少了其使用。目前检测到的对现有药物的耐药性使得人们对链霉素重新产生了兴趣。其作用机制集中在核糖体上，抑制微生物的蛋白质合成。当编码16S rRNA和蛋白质S12的基因发生突变时，就会出现耐药性。我们研究了链霉素对899株结核分枝杆菌菌株的作用，其中713株来自肺部分离株，186株来自肺外分离株。最初使用的是BACTEC 460 TB系统以及ESP II系统。作为对照，使用了ATCC27294模式菌株（对链霉素、利福平、乙胺丁醇和异烟肼敏感）。结果显示，所有病例中的继发耐药率为2.1%。在12株菌株中观察到多重耐药。
